NASDAQ: CADLCandel Therapeutics Inc Stock
$1.53+0.02 (+1.32%)
Updated Jun 2, 2023
CADL Price
$1.53
Fair Value Price
N/A
Market Cap
$44.25M
52 Week Low
$1.15
52 Week High
$4.25
P/E
-1.68x
P/B
1.12x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$26.72M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.7
Operating Cash Flow
-$34M
Beta
1.21
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CADL Overview
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for cancer patients. Its pipeline includes CAN-2409, in Phase II clinical trials for the treatment of pancreatic cancer, Phase III clinical trials for the treatment of prostate cancer, Phase II clinical trials for the treatment of lung cancer, and Phase Ib/II clinical trials (completed) for the treatment of high-grade glioma. The company is also developing CAN-3110, in Phase I clinical trials for the treatment of recurrent glioblastoma. Candel Therapeutics was incorporated in 2003 and is based in Needham, MA.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CADL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CADL is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CADL is good value based on its book value relative to its share price (1.12x), compared to the US Biotechnology industry average (5.2x)
P/B vs Industry Valuation
CADL is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CADL due diligence checks available for Premium users.
Be the first to know about important CADL news, forecast changes, insider trades & much more!
CADL News
Valuation
CADL fair value
Fair Value of CADL stock based on Discounted Cash Flow (DCF)
Price
$1.53
Fair Value
$4.67
Undervalued by
67.25%
CADL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CADL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.68x
Industry
11.51x
Market
52.69x
CADL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.12x
Industry
5.2x
CADL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CADL's financial health
Profit margin
Revenue
$0.0
Net Income
-$8.8M
Profit Margin
0%
CADL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$67.2M
Liabilities
$27.6M
Debt to equity
0.7
CADL's short-term assets ($61.88M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CADL's short-term assets ($61.88M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CADL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.8M
Investing
$19.0k
Financing
$0.0
CADL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CADL vs Biotech Stocks
Candel Therapeutics Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.